Human Cot-1 DNA

Human Cot-1 DNA The HUS Group requests tenders for Human Cot-1 DNA . Human Cot-1 DNA is a reagent used in the array process during hybridization. The procurement includes the following products: - Product group 1: Human Cot-1 DNA The procurement is not divided into lots. The estimated consumption of Human Cot-1 DNA per year would be around 21 600 µg. The product is described in more detail in below the invitation to tender and in Appendix 2 (Price and Product Form). The goal of this competitive procurement is to have good product delivery reliability and to have products available when they are needed. The most economically advantageous tender shall be selected. The criterion for determining the most economically advantageous tender shall be the lowest price. Quality is taken into account as minimum requirements. The procedure for carrying out the comparison, as well as the associated calculation formulas, are explained in more detail in Appendix 2 (Price and Product Form) and in the "General criteria of the group" section. The Agreement is in force for a fixed period of 2 years, and thereafter until terminated. The aim is to bring the agreement into force as soon as possible after the procurement procedure has been completed. The estimated starting day for the contract period is 30.4.2026. The products requested in this invitation to tender will be used by the Genetics Laboratory of the HUS Diagnostic Center (Helsinki University Hospital, HUS Group). See Appendix 1 (Agreement) of the call for tenders for details. The total estimated value of the procurement (VAT 0%) is approximately EUR 80 000 for 48 months. This is an estimate and the contracting entity does not commit neither to the stated euro amounts and nor the consumption figures indicated in the invitation to tender. The final order quantities may be higher or lower than stated. The subject matter and requirements of the procurement are described in detail in the invitation to tender and its annexes.,